Click Activated Protodrugs Against Cancer (CAPAC™)

Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to deliver unprecedented doses precisely focused at the tumor with an uncharacteristically mild safety profile - breaking through the historic ceiling of dose-limiting toxicities. Shasqi’s CAPAC Platform is highly modular and can be applied to a broad range of cancer drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.

Click chemistry can be applied to existing technologies to improve safety and efficacy for cancer patients:

  1. Alternative to antibody drug conjugates
  2. Alternative to bispecific immune cell engager antibodies
  3. Tumor localization of immune effector molecules
  4. Tumor localization of radiopharmaceuticals

Our lead program directs powerful therapies precisely to tumors

SQ3370 is the first click chemistry-based therapy to be administered in human clinical studies and is in development for the treatment of sarcoma and other solid tumors. SQ3370, works by enabling a chemical “click” reaction between a biopolymer that is injected into the target tumor area and an intravenously infused protodrug which contains the highly cytotoxic chemotherapy doxorubicin. The doxorubicin is not released until it reacts locally with the biopolymer. Interim clinical data from a Phase 1 clinical study of SQ3370 in advanced sarcomas and other solid tumors, provides initial validation for Shasqi’s platform, demonstrating an encouraging safety profile, increased tumor exposure to active drug, and early signs of clinical activity.

While our initial program aims to improve the efficacy and tolerability of a widely used chemotherapy, our platform enables us to look across the spectrum of the industry’s most powerful tumor killing therapies with a new lens. We are working to develop next-generation click-chemistry therapies that enable us to use even more powerful payloads and localize drugs at tumors that cannot be safely administered using conventional approaches. There is an enormous opportunity to dramatically improve the efficacy of powerful therapies by localizing them, which could help increase the number of patients who benefit.